<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607111416483</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607111416483</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Communications</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prevalence of Vitamin D Deficiency and Response to Oral Vitamin D Supplementation in Patients Receiving Home Parenteral Nutrition</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kumar</surname><given-names>Puja R.</given-names></name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="aff1-0148607111416483">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fenton</surname><given-names>Tanis R.</given-names></name>
<degrees>RD</degrees>
<xref ref-type="aff" rid="aff2-0148607111416483">2</xref>
<xref ref-type="aff" rid="aff3-0148607111416483">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shaheen</surname><given-names>Abdel A.</given-names></name>
<degrees>MD, MSc</degrees>
<xref ref-type="aff" rid="aff1-0148607111416483">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Raman</surname><given-names>Maitreyi</given-names></name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="aff1-0148607111416483">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607111416483"><label>1</label>Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada</aff>
<aff id="aff2-0148607111416483"><label>2</label>Nutrition Services, Alberta Health Services, Calgary, Alberta, Canada</aff>
<aff id="aff3-0148607111416483"><label>3</label>Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada</aff>
<author-notes>
<corresp id="corresp1-0148607111416483">Maitreyi Raman, MD, FRCPC, Division of Gastroenterology, University of Calgary, 6D26, Teaching, Research and Wellness Building, 3280 Hospital Dr NW, Calgary, AB, Canada T2N 4N1; e-mail: <email>mkothand@ucalgary.ca</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>36</volume>
<issue>4</issue>
<fpage>463</fpage>
<lpage>469</lpage>
<history>
<date date-type="received">
<day>1</day>
<month>4</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>6</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p>The purpose of this study was to document vitamin D status in home parenteral nutrition (HPN) patients and determine if oral vitamin D supplementation has a substantial effect. <italic>Methods</italic>: A retrospective chart review of eligible adults enrolled in the Southern Alberta Home Parenteral Nutrition program (n = 15) for a minimum of 6 months was conducted. Serum measurements of 25OHD were recorded and patients were categorized by vitamin D status as follows: sufficient; insufficient; deficient with respective levels of 25OHD ≥75 nmol/L, 27.5–75 nmol/L, and ≤27.5 nmol/L; and mixed. <italic>Results</italic>: Five of 15 patients had insufficient vitamin D status throughout the study period; all had short bowel syndrome. Nine were in the mixed category; 1 was consistently sufficient, and no one was consistently deficient. Patient demographics were similar between the insufficient and mixed groups. There were no significant differences in health outcomes between the insufficient and mixed vitamin D status groups. The median (interquartile range) dose and duration of vitamin D3 supplementation for the insufficient group was 5000 IU/d (4,000–7,143) for 1,175 (1,145–1,578) total days compared to 3,000 IU/d (1,000–7,143) for 1,529 (111–1,980) days for the mixed group. <italic>Conclusions</italic>: Most patients receiving HPN had insufficient vitamin D status. When prescribed high doses of oral vitamin D, patients did not consistently achieve appropriate 25OHD levels. Alternate routes of vitamin D supplementation in patients receiving HPN should be considered. Large multicenter prospective studies are needed to best characterize the relationship between vitamin D dosing for HPN patients and vitamin D status.</p>
</abstract>
<kwd-group>
<kwd>home parenteral nutrition</kwd>
<kwd>vitamin D</kwd>
<kwd>oral vitamin D supplementation</kwd>
<kwd>health outcomes</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607111416483">
<title>Clinical Relevancy Statement</title>
<p>A number of studies have highlighted the prevalence of vitamin D deficiency in patients receiving home parenteral nutrition (HPN). This underscores the need for routinely screening and initiating supplementation in this population in addition to determining dosage and route of delivery where applicable. As far as we are aware, there are no evidence-based guidelines for monitoring and treating vitamin D deficiency in this population. Our study is the first to describe vitamin D status based on serum levels of 25-hydroxy vitamin D in the setting of oral supplementation in HPN patients. Although the patients in our study were receiving relatively high oral doses, response was variable, suggesting the need for further research into alternative methods of supplementation such as ultraviolet therapy.</p>
</sec>
<sec id="section2-0148607111416483" sec-type="intro">
<title>Introduction</title>
<p>There has been a resurgence of interest in vitamin D because of mounting evidence revolving around its nonskeletal effects. Some of the nontraditional functions ascribed to vitamin D include roles in infection modulation, autoimmune-mediated disorders, cardiac disease, and malignancies. Patients who require parenteral nutrition (PN) are not only at high risk of vitamin D deficiency but also at high risk of conditions that have been recently associated with vitamin D deficiency such as sepsis.<sup><xref ref-type="bibr" rid="bibr1-0148607111416483">1</xref><xref ref-type="bibr" rid="bibr2-0148607111416483"/><xref ref-type="bibr" rid="bibr3-0148607111416483"/><xref ref-type="bibr" rid="bibr4-0148607111416483"/>-<xref ref-type="bibr" rid="bibr5-0148607111416483">5</xref></sup></p>
<p>Most patients requiring home PN (HPN) have intestinal failure, many secondary to short bowel syndrome (SBS), which is known to result in poor intestinal absorption and in particular fat malabsorption, which could lead to vitamin D deficiency.<sup><xref ref-type="bibr" rid="bibr6-0148607111416483">6</xref></sup> Patients requiring HPN may be at particularly high risk of vitamin D deficiency because they may lack adequate ultraviolet B (UVB) exposure primarily from sunlight due to chronic illness, have inadequate oral intake of vitamin D–rich foods, and comorbidities/coingestions that affect vitamin D metabolism. Patients receiving HPN usually only receive at most 200 International Units (IU) of vitamin D as part of their injectable multivitamin, which is less than recommended in recent guidelines.<sup><xref ref-type="bibr" rid="bibr7-0148607111416483">7</xref></sup> Screening for vitamin D deficiency with plasma total 25-hydroxyvitamin D is recommended as routine care for all patients requiring HPN.<sup><xref ref-type="bibr" rid="bibr8-0148607111416483">8</xref></sup></p>
<p>There appears to be some evidence for an antibacterial role for vitamin D, as extrapolated from the tuberculosis literature.<sup><xref ref-type="bibr" rid="bibr9-0148607111416483">9</xref></sup> Observational studies suggest an association between vitamin D deficiency and development of infections, including influenza and tuberculosis.<sup><xref ref-type="bibr" rid="bibr9-0148607111416483">9</xref><xref ref-type="bibr" rid="bibr10-0148607111416483"/>-<xref ref-type="bibr" rid="bibr11-0148607111416483">11</xref></sup> Vitamin D may prevent infections as it may be a key regulator of the immune system and may exert some direct antimicrobial effects by production of defensins.<sup><xref ref-type="bibr" rid="bibr12-0148607111416483">12</xref></sup> Vitamin D receptors are found on a majority of immune cells, including peripheral blood monocytes, leukocytes, antigen-presenting cells, and T lymphocytes, implying that vitamin D has a role to play in the regulation of the innate immune system.<sup><xref ref-type="bibr" rid="bibr8-0148607111416483">8</xref>,<xref ref-type="bibr" rid="bibr13-0148607111416483">13</xref><xref ref-type="bibr" rid="bibr14-0148607111416483"/><xref ref-type="bibr" rid="bibr15-0148607111416483"/>-<xref ref-type="bibr" rid="bibr16-0148607111416483">16</xref></sup> In addition, some cells such as T lymphocytes have been shown to express the 1,25 hydroxylase enzyme, which may have clinical effects on inflammation, immunity, and infection. Unfortunately, to date, limited randomized control data support that vitamin D supplementation may prevent infections,<sup><xref ref-type="bibr" rid="bibr17-0148607111416483">17</xref></sup> although the biological plausibility is clear.</p>
<p>The purpose of this retrospective cohort study is to document vitamin D status in outpatients requiring HPN in the Calgary Health Region and their response to oral vitamin D therapy, as well as explore the possibility of an association between vitamin D status, infections, and other health outcome measures in patients receiving HPN.</p>
</sec>
<sec id="section3-0148607111416483" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>A retrospective chart review of eligible adults (&gt;18 years old) enrolled in the Southern Alberta Home Parenteral Nutrition program since 2007 (when routine serum 25OHD levels became part of monitoring practices), for a minimum of 6 months was conducted (n = 15). Oral vitamin D<sub>3</sub> supplementation was prescribed for patients identified to have a 25OHD level below 75 nmol/L. Patients were excluded from this study if they were receiving intradialytic PN.</p>
<p>A list of patients who received home PN was obtained from the Southern Alberta Home Parental program. Demographic information, including age, gender, PN indication and prescription, oral intake/enteral nutrition details, comorbidities that may have affected vitamin D homeostasis (inflammatory bowel disease [IBD], celiac disease, liver disease, renal disease, as well as pertinent surgical history), and medications, including oral vitamin D supplementation used during the study period, were extracted from the charts. Vitamin D intake was calculated on a per day basis. All patients received routine intravenous (IV) multivitamin supplementation, which included 200 IU of vitamin D (cholecalciferol). However, because some patients did not receive HPN daily, the intravenous quantity was small, and therefore vitamin D provided in the PN solution was not included in the total vitamin D supplementation calculation. Specific infectious health outcomes were collected over the same time period, including catheter-related infections with documentation of positive blood cultures, non-catheter-related infections with documentation of positive urine culture, or convincing chest X-ray with elevated white blood cells. Noninfectious health outcomes were also collected over the same time period, including PN-related liver disease, pancreatitis, hyperglycemia, and mortality.</p>
<p>Patients were categorized by degree of deficiency based on the following vitamin D serum levels: (1) vitamin D sufficient, 25OHD &gt;75 nmol/L; (2) insufficient, 25OHD 27.5–75 nmol/L; (3) deficient, 25OHD ≤27.5 nmol/L<sup><xref ref-type="bibr" rid="bibr18-0148607111416483">18</xref></sup>; and (4) mixed. For example, if an individual patient at one point during the study period had a deficient 25OHD and another point was insufficient, then he or she was categorized into the fourth category, which was called “mixed.” The median 25OHD level, dose of supplementation, and duration of supplementation were documented for each patient and compared between the groups and examined over time. One patient who was an ardent sun tanner was not included in the study analysis because including this patient might have distorted our conclusions. As would be expected, there were no patients persistently within the deficient category because once identified to be deficient, these individuals were given oral vitamin D supplementation and followed with serial 25OHD levels to ensure improvement. Hence, analysis was done on the 2 remaining groups, the insufficient and mixed groups. A sensitivity analysis was conducted to examine the vitamin D status by PN indications.</p>
<p>Descriptive statistics were calculated as frequencies, medians, interquartile ranges, time durations, and weighted averages. Fisher exact tests were used to compare frequencies, and the Kruskal-Wallis test was used to compare vitamin D intakes between the vitamin D status groups. All <italic>P</italic> values were 2-sided tests.</p>
</sec>
<sec id="section4-0148607111416483" sec-type="results">
<title>Results</title>
<p>The ardent sun tanner, who had sufficient vitamin D status throughout the study period without receiving oral supplementation, was not examined further. Thus, of our 15 patients on HPN for longer than 6 months, 14 were included in the analysis. These 14 patients were receiving HPN for a variety of reasons (<xref ref-type="table" rid="table1-0148607111416483">Table 1</xref>). Five of 14 patients were insufficient throughout the study period, all with SBS, whereas the 9 individuals in the mixed vitamin D status category had a variety of indications for HPN (<xref ref-type="table" rid="table1-0148607111416483">Table 1</xref>). Patient demographics were similar between the insufficient and mixed groups (<xref ref-type="table" rid="table1-0148607111416483">Table 1</xref>). No patient remained in the deficient category throughout the study period.</p>
<table-wrap id="table1-0148607111416483" position="float">
<label>Table 1.</label>
<caption><p>Patient Characteristics Between the Insufficient and Mixed Groups</p></caption>
<graphic alternate-form-of="table1-0148607111416483" xlink:href="10.1177_0148607111416483-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Insufficient (n = 5)</th>
<th align="center">Mixed (n = 9)</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y, median (IQR)</td>
<td>60 (50–65)</td>
<td>55 (46–71)</td>
<td>.9</td>
</tr>
<tr>
<td>Female gender, No. (%)</td>
<td>5 (100)</td>
<td>6 (67)</td>
<td>.26</td>
</tr>
<tr>
<td>Body mass index, median (IQR)</td>
<td>21 (17–27)</td>
<td>19 (15–20)</td>
<td>.32</td>
</tr>
<tr>
<td colspan="4">Indications, No. (%)</td>
</tr>
<tr>
<td> Short bowel syndrome</td>
<td>5 (100)</td>
<td>4 (44)</td>
<td>.09</td>
</tr>
<tr>
<td> Crohn disease</td>
<td>0</td>
<td>1 (11)</td>
<td>1.0</td>
</tr>
<tr>
<td> Intestinal pseudo-obstruction</td>
<td>0</td>
<td>3 (33)</td>
<td>.26</td>
</tr>
<tr>
<td> Small bowel obstruction</td>
<td>0</td>
<td>1 (11)</td>
<td>1.0</td>
</tr>
<tr>
<td>Renal Failure, No. (%)</td>
<td>2 (40)</td>
<td>2 (22)</td>
<td>.58</td>
</tr>
<tr>
<td>Baseline creatinine, median (IQR)</td>
<td>79 (73–80)</td>
<td>78 (62–83)</td>
<td>.64</td>
</tr>
<tr>
<td colspan="4">Comorbidities, No. (%)</td>
</tr>
<tr>
<td> Celiac disease</td>
<td>0</td>
<td>1</td>
<td>1.0</td>
</tr>
<tr>
<td> Inflammatory bowel disease</td>
<td>3 (60)</td>
<td>3 (33)</td>
<td>.58</td>
</tr>
<tr>
<td> Liver disease</td>
<td>0</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td> Osteoporosis</td>
<td>2 (40)</td>
<td>5 (56)</td>
<td>1.0</td>
</tr>
<tr>
<td> Hypothyroidism</td>
<td>1 (20)</td>
<td>0</td>
<td>.36</td>
</tr>
<tr>
<td colspan="4">Drugs, No. (%)</td>
</tr>
<tr>
<td> Steroids</td>
<td>0</td>
<td>2 (22)</td>
<td>.51</td>
</tr>
<tr>
<td> Bisphos</td>
<td>1 (20)</td>
<td>3 (33)</td>
<td>1.0</td>
</tr>
<tr>
<td> HCTZ</td>
<td>0</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td> Lasix</td>
<td>0</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td> Heparin</td>
<td>1 (20)</td>
<td>3 (33)</td>
<td>1.0</td>
</tr>
<tr>
<td> L-Thyroxine</td>
<td>1 (20)</td>
<td>0</td>
<td>.36</td>
</tr>
<tr>
<td> Vitamin D supplements</td>
<td>5 (100)</td>
<td>9 (100)</td>
<td>NA</td>
</tr>
<tr>
<td colspan="4">PN prescription, median (IQR)</td>
</tr>
<tr>
<td> Calories, kcal</td>
<td>1,324 (1,038–1,400)</td>
<td>1,670 (1,286–2,000)</td>
<td>.29</td>
</tr>
<tr>
<td> Dextrose, g</td>
<td>206 (190–220)</td>
<td>250 (190–300)</td>
<td>.39</td>
</tr>
<tr>
<td> Lipid, mL</td>
<td>200 (180–210)</td>
<td>250 (190–282)</td>
<td>.32</td>
</tr>
<tr>
<td> Protein, g</td>
<td>68 (54–70)</td>
<td>80 (65–100)</td>
<td>.32</td>
</tr>
<tr>
<td>Vitamin D level, nmol/L, median (IQR)</td>
<td>52 (43–53)</td>
<td>75 (64–86)</td>
<td>.07</td>
</tr>
<tr>
<td>Vitamin D supplement, IU, median (IQR)</td>
<td>5,000 (4,000–7,143)</td>
<td>3,000 (1,000–7,143)</td>
<td>.50</td>
</tr>
<tr>
<td>Duration of supplementation, d, median (IQR)</td>
<td>1,175 (1,145–1,578)</td>
<td>1,529 (111–1,980)</td>
<td>.95</td>
</tr>
<tr>
<td>PN length, d, median (IQR)</td>
<td>1,092 (755–4,166)</td>
<td>2,011 (546–4,840)</td>
<td>.84</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607111416483">
<p>IQR, interquartile range; IU, International Units; NA, not applicable; PN, parenteral nutrition.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The patients categorized into the mixed group included both SBS and other indications for HPN. These patients spent nearly equal amounts of time in both the sufficient and insufficient state. Although the oral vitamin D supplementation doses during the sufficient and insufficient phases were similar and higher than during the deficient phases within the mixed group (<xref ref-type="table" rid="table2-0148607111416483">Table 2</xref>), these differences were not statistically significant (<italic>P</italic> = .14).</p>
<table-wrap id="table2-0148607111416483" position="float">
<label>Table 2.</label>
<caption><p>Duration, Weight Averages of Serum 25OHD, and Doses of Oral Supplement by Vitamin D Status Within the Mixed Group (n = 9)</p></caption>
<graphic alternate-form-of="table2-0148607111416483" xlink:href="10.1177_0148607111416483-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">Duration, d</th>
<th align="center">25OHD, nmol/L</th>
<th align="center" colspan="2">Supplementation, IU/d</th>
</tr>
<tr>
<th/>
<th align="center">Weighted Average</th>
<th align="center">Median (IQR)</th>
<th align="center">Weighted Average</th>
<th align="center">Weighted Average</th>
<th align="center">Median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sufficient status</td>
<td>427</td>
<td>479 (223–611)</td>
<td>105</td>
<td>7,074</td>
<td>2,500 (1,000–3,000)</td>
</tr>
<tr>
<td>Insufficient status</td>
<td>302</td>
<td>350 (131–431)</td>
<td>51</td>
<td>6,364</td>
<td>3,000 (500–7,143)</td>
</tr>
<tr>
<td>Deficient status</td>
<td>188</td>
<td>189 (188–1,762)</td>
<td>23</td>
<td>173</td>
<td>0 (0–500)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0148607111416483">
<p>IQR, interquartile range.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>There were no significant differences in incidence of infections, hyperglycemia, and prevalence of liver disease, pancreatitis, or mortality between the insufficient and mixed vitamin D status groups (<xref ref-type="table" rid="table3-0148607111416483">Table 3</xref>).</p>
<table-wrap id="table3-0148607111416483" position="float">
<label>Table 3.</label>
<caption><p>Infectious and Noninfectious Outcomes Between the Insufficient and Mixed Groups</p></caption>
<graphic alternate-form-of="table3-0148607111416483" xlink:href="10.1177_0148607111416483-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Insufficient (n = 5)</th>
<th align="center">Mixed (n = 9)</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">Infectious outcomes</td>
</tr>
<tr>
<td> Incidence of catheter infections</td>
<td>3/5</td>
<td>3/9</td>
<td>.58</td>
</tr>
<tr>
<td>  &gt;1 catheter infection</td>
<td>0/3</td>
<td>2/3</td>
<td>.40</td>
</tr>
<tr>
<td> Incidence of noncatheter infections</td>
<td>1/5</td>
<td>3/9</td>
<td>1.0</td>
</tr>
<tr>
<td>  &gt;1 noncatheter infections</td>
<td>0/1</td>
<td>1/3</td>
<td>1.0</td>
</tr>
<tr>
<td> Incidence of with urinary infections</td>
<td>2/5</td>
<td>6/9</td>
<td>.58</td>
</tr>
<tr>
<td>  &gt;1 urinary infection</td>
<td>1/2</td>
<td>3/6</td>
<td>1.0</td>
</tr>
<tr>
<td> Incidence of pulmonary infections</td>
<td>0/5</td>
<td>1/9</td>
<td>1.0</td>
</tr>
<tr>
<td>  &gt;1 pulmonary infection</td>
<td>0</td>
<td>0/1</td>
<td>NA</td>
</tr>
<tr>
<td colspan="4">Other outcomes</td>
</tr>
<tr>
<td> Hyperglycemia</td>
<td>0</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td> Pancreatitis</td>
<td>1</td>
<td>0</td>
<td>.36</td>
</tr>
<tr>
<td> Biopsy-proven intrahepatic cholestasis</td>
<td>1</td>
<td>4</td>
<td>.58</td>
</tr>
<tr>
<td> Liver enzyme elevation</td>
<td>2</td>
<td>4</td>
<td>1.0</td>
</tr>
<tr>
<td> Mortality</td>
<td>1</td>
<td>3</td>
<td>1.0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0148607111416483">
<p>NA, not applicable.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In the sensitivity analysis, 2 SBS patients responded well to supplementation, increasing their serum 25OHD into the sufficient range (<xref ref-type="fig" rid="fig1-0148607111416483">Figure 1</xref>); their weighted average intake of daily vitamin D was 2748 IU, whereas the remainder of the SBS patients did not achieve satisfactory serum 25OHD response despite a median weighted average intake of vitamin D of 3859 IU/d. The vitamin D status of patients enrolled in the HPN program for indications other than SBS had varied responses to vitamin D supplementation (<xref ref-type="fig" rid="fig2-0148607111416483">Figure 2</xref>). One patient’s status improved on an intake of 22,000 IU/d, 1 patient’s vitamin D status declined markedly on 7,143 IU/d, 1 patient’s status remained borderline deficient despite an intake of 4670 IU/d, and the fourth patient who initially was sufficient became insufficient while on HPN with no prescribed oral vitamin D supplementation.</p>
<fig id="fig1-0148607111416483" position="float">
<label>Figure 1.</label>
<caption><p>Vitamin D status in patients with short bowel syndrome where each line represents a different individual within the home parenteral nutrition program. Dashed parallel lines represent the borders between the deficient, insufficient, and sufficient ranges.</p></caption>
<graphic xlink:href="10.1177_0148607111416483-fig1.tif"/>
</fig>
<fig id="fig2-0148607111416483" position="float">
<label>Figure 2.</label>
<caption><p>Vitamin D status in patients on home parenteral nutrition for indications other than short bowel syndrome. Dashed parallel lines represent the borders between the deficient, insufficient, and sufficient ranges.</p></caption>
<graphic xlink:href="10.1177_0148607111416483-fig2.tif"/>
</fig>
</sec>
<sec id="section5-0148607111416483" sec-type="discussion">
<title>Discussion</title>
<p>This is the first study to describe vitamin D status in the setting of oral supplementation in HPN patients, to our knowledge. In our retrospective study, after excluding the patient who suntanned extensively from further analysis, all of the eligible patients had insufficient 25OHD levels at least once during routine 25OHD assessment. Oral supplementation helped some patients improve their vitamin D levels, whereas other patients did not achieve sufficient status despite high oral doses. None of the patients in the insufficient group, all of whom were receiving HPN for SBS, were able to achieve sufficient status despite high oral doses. We speculate that the difficulty by the SBS patients to achieve sufficient vitamin D status may be a function of their residual length of bowel more than the actual oral dose of vitamin D provided. We are unable to comment on compliance in this study. In our non-SBS patients, the response to vitamin D supplementation was varied, with no discernable pattern.</p>
<p>Our data did not reveal any significant associations between vitamin D status and incidence of infectious and noninfectious outcomes, but our study was limited by sample size, and our lack of association does not preclude these associations existing in this population. These patients are at increased risk of both vitamin D insufficiency and infections, and larger studies may identify vitamin D insufficiency as an important risk factor.</p>
<p>The vitamin D level that may offer protection against disease is still undetermined, but many believe that serum 25OHD should be at least 75 nmol/L to provide adequate immunomodulatory effects.<sup><xref ref-type="bibr" rid="bibr8-0148607111416483">8</xref>,<xref ref-type="bibr" rid="bibr19-0148607111416483">19</xref>-<xref ref-type="bibr" rid="bibr20-0148607111416483">20</xref></sup> Until recently, little was known about vitamin D levels in patients receiving PN. A small U.S. study in patients receiving HPN reported a prevalence rate of 77% of vitamin D deficiency, defined as 25OHD &lt;75 nmol/L.<sup><xref ref-type="bibr" rid="bibr21-0148607111416483">21</xref></sup> Similarly, a study from Canada found that all 22 patients within the HPN program who were not receiving additional vitamin D supplements had subnormal 25OHD levels, defined as &lt;75 nmol/L, and 65% had levels &lt;50 nmol/L.<sup><xref ref-type="bibr" rid="bibr22-0148607111416483">22</xref></sup> Both these above-mentioned studies reinforce our findings that vitamin D insufficiency is prevalent among patients in HPN programs.</p>
<p>As far as we are aware, there are no evidence-based guidelines for monitoring vitamin D status for this population. The European Society of Parenteral Nutrition HPN guidelines recommend yearly measurements of 25OHD levels for all patients enrolled in an HPN program.<sup><xref ref-type="bibr" rid="bibr23-0148607111416483">23</xref></sup> A survey of European home PN programs revealed that only 14% of programs performed vitamin D assays at every home visit, whereas the remainder reported that vitamin D was monitored regularly, but time intervals were not specified.<sup><xref ref-type="bibr" rid="bibr24-0148607111416483">24</xref></sup> The American Society for Parenteral and Enteral Nutrition guidelines and the recently developed Australian Society of Parenteral Nutrition guidelines do not address vitamin D monitoring in HPN patients specifically.<sup><xref ref-type="bibr" rid="bibr25-0148607111416483">25</xref>,<xref ref-type="bibr" rid="bibr26-0148607111416483">26</xref></sup> Numerous authors recommend yearly monitoring of numerous vitamins in HPN patients, including vitamin D,<sup><xref ref-type="bibr" rid="bibr8-0148607111416483">8</xref>,<xref ref-type="bibr" rid="bibr27-0148607111416483">27</xref>,<xref ref-type="bibr" rid="bibr28-0148607111416483">28</xref></sup> without guidance regarding vitamin D replacement strategies.</p>
<p>Many patients receiving HPN have underlying gastrointestinal disorders that would likely impair absorption of oral vitamin D. In our study, 10 patients (71%) were on HPN due to SBS. As far as we are aware, no published studies have examined the effectiveness of high oral doses in these patients to achieve sustained normal vitamin D status. A small study of 10 HPN patients found that 50% of these patients with PN dependency due to intestinal failure failed to improve their vitamin D status while on supplements ranging from 160–700 IU daily.<sup><xref ref-type="bibr" rid="bibr29-0148607111416483">29</xref></sup> Deluca<sup><xref ref-type="bibr" rid="bibr19-0148607111416483">19</xref></sup> suggests starting at 50,000 IU oral vitamin D weekly for these patients and adjusting the dose according to the response. Supplementation in this patient group could take the form of oral tablets, oral vitamin D drops, UVB light therapy, and/or IV supplementation. As far as we are aware, other vitamin D replacement forms such as UV therapy and parenteral formulations have not been formally studied. Bioavailability and response data to help guide healthcare providers are lacking. Thompson and Duerksen’s approach<sup><xref ref-type="bibr" rid="bibr22-0148607111416483">22</xref></sup> to maintaining sufficient vitamin D status in HPN patients is to routinely start all patients on supplements, initially at 1,000 IU/d, and proceed to 50,000 IU/wk if this fails to normalize vitamin D status. Another approach proposed by Pittas et al<sup><xref ref-type="bibr" rid="bibr8-0148607111416483">8</xref></sup> in their recent review of vitamin D in adults requiring nutrition support suggests, for patients with 25OHD &lt;75 nmol/L, initiating therapy with 50,000 IU/wk for 12 weeks followed by 1,000 IU daily. Considering our findings and the lack of a consistent response in most of our patients to oral supplementation, we favor the approach of routine supplementation, monitoring response and titration to higher doses as required. Vitamin D toxicity is rare and has been observed only when dietary intake exceeds 10,000 IU/d in patients with a normal gastrointestinal tract.<sup><xref ref-type="bibr" rid="bibr30-0148607111416483">30</xref></sup> Considering that HPN patients often have SBS and other causes of intestinal failure leading to malabsorption, doses in the 10,000 IU/d range are not inconceivable.</p>
<p>Vitamin D deficiency among PN patients may be implicated in the pathogenesis of common PN-related complications such as sepsis and metabolic bone disease.<sup><xref ref-type="bibr" rid="bibr31-0148607111416483">31</xref></sup> There is emerging evidence in the critically ill patient population that vitamin D status may have an impact on length of stay in intensive care units, increased risk of pneumonia, and elevated organ failure scores.<sup><xref ref-type="bibr" rid="bibr32-0148607111416483">32</xref></sup> A recent study reported an association between 28-day all-cause mortality and poor vitamin D status among critically ill patients.<sup><xref ref-type="bibr" rid="bibr33-0148607111416483">33</xref></sup> We recognize that many of the risk factors for vitamin D deficiency are risk factors for acute and chronic medical conditions, potentially making vitamin D status an excellent marker for overall health. The association with mortality is difficult to delineate because of potential unmeasured confounding factors in our study. Further study is required regarding the role of vitamin D in immunity, infections, and glucose homeostasis in the HPN population. Considering the small numbers of patients on HPN in a single center, the optimal method of vitamin D replacement will likely require a multicenter design.</p>
</sec>
<sec id="section6-0148607111416483" sec-type="conclusions">
<title>Conclusion</title>
<p>Vitamin D deficiency is prevalent among recipients of HPN. P receiving HPN should be routinely screened and treated with individualized supplementation and monitoring practices. Oral supplementation at high doses may help improve vitamin D deficiency, but the appropriate method of delivery, dose, and duration have not yet been established. Our data suggest that patients with SBS will need high average daily doses to maintain reasonable vitamin D status. Further research is required to best characterize the relationship between health outcomes and vitamin D status in addition to the best method for vitamin D replacement in patients with intestinal failure on HPN.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607111416483">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ugur</surname><given-names>A</given-names></name>
<name><surname>Marashdeh</surname><given-names>BH</given-names></name>
<name><surname>Gottschalck</surname><given-names>I</given-names></name>
<name><surname>Brobech Mortensen</surname><given-names>P</given-names></name>
<name><surname>Staun</surname><given-names>M</given-names></name>
<name><surname>Bekker Jeppesen</surname><given-names>P</given-names></name>
</person-group>. <article-title>Home parenteral nutrition in Denmark in the period from 1996 to 2001</article-title>. <source>Scand J Gastroenterol</source>. <year>2006</year>;<volume>41</volume>:<fpage>401</fpage>-<lpage>407</lpage>.</citation>
</ref>
<ref id="bibr2-0148607111416483">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shirotani</surname><given-names>N</given-names></name>
<name><surname>Lino</surname><given-names>T</given-names></name>
<name><surname>Numata</surname><given-names>K</given-names></name>
<name><surname>Kameoka</surname><given-names>S</given-names></name>
</person-group>. <article-title>Complications of central venous catheters in patients on home parenteral nutrition: an analysis of 68 patients over 16 years</article-title>. <source>Surg Today</source>. <year>2006</year>;<volume>36</volume>:<fpage>420</fpage>-<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr3-0148607111416483">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reimund</surname><given-names>JM</given-names></name>
<name><surname>Arondel</surname><given-names>Y</given-names></name>
<name><surname>Finck</surname><given-names>G</given-names></name>
<name><surname>Zimmermann</surname><given-names>F</given-names></name>
<name><surname>Duclos</surname><given-names>B</given-names></name>
<name><surname>Baumann</surname><given-names>R</given-names></name>
</person-group>. <article-title>Catheter-related infection in patients on home parenteral nutrition: results of a prospective survey</article-title>. <source>Clin Nutr</source>. <year>2002</year>;<volume>21</volume>:<fpage>33</fpage>-<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr4-0148607111416483">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freshwater</surname><given-names>DA</given-names></name>
<name><surname>Saadeddin</surname><given-names>A</given-names></name>
<name><surname>Deel-Smith</surname><given-names>P</given-names></name>
<name><surname>Digger</surname><given-names>T</given-names></name>
<name><surname>Jones</surname><given-names>BJ</given-names></name>
</person-group>. <article-title>Can home parenteral nutrition be provided by non-specialised centres? 2300 weeks of experience at a district general hospital in the United Kingdom</article-title>. <source>Clin Nutr</source>. <year>2005</year>;<volume>24</volume>:<fpage>229</fpage>-<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr5-0148607111416483">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ireton-Jones</surname><given-names>C</given-names></name>
<name><surname>DeLegge</surname><given-names>M</given-names></name>
</person-group>. <article-title>Home parenteral nutrition registry: a five year retrospective evaluation of outcomes of patients receiving home parenteral nutrition support</article-title>. <source>Nutrition</source>. <year>2005</year>;<volume>21</volume>:<fpage>156</fpage>-<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr6-0148607111416483">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bikle</surname><given-names>DD</given-names></name>
</person-group>. <article-title>Vitamin D insufficiency/deficiency in gastrointestinal disorders</article-title>. <source>J Bone Miner Res</source>. <year>2007</year>;<volume>22</volume>(<issue>suppl 2</issue>):<fpage>V50</fpage>-<lpage>V54</lpage>.</citation>
</ref>
<ref id="bibr7-0148607111416483">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanley</surname><given-names>DA</given-names></name>
<name><surname>Cranney</surname><given-names>A</given-names></name>
<name><surname>Jones</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Vitamin D in Adult health and disease: a review and guideline statement from Osteoporosis Canada</article-title>. <source>CMAJ</source>. <year>2010</year>;<volume>182</volume>:<fpage>1315</fpage>-<lpage>1319</lpage>.</citation>
</ref>
<ref id="bibr8-0148607111416483">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pittas</surname><given-names>AG</given-names></name>
<name><surname>Laskowksi</surname><given-names>U</given-names></name>
<name><surname>Kos</surname><given-names>L</given-names></name>
<name><surname>Saltzman</surname><given-names>E</given-names></name>
</person-group>. <article-title>Role of vitamin D in adults requiring nutrition support</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2010</year>;<volume>34</volume>:<fpage>70</fpage>-<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr9-0148607111416483">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chan</surname><given-names>TY</given-names></name>
</person-group>. <article-title>Vitamin D deficiency and susceptibility to tuberculosis</article-title>. <source>Calcif Tussue Int</source>. <year>2000</year>;<volume>66</volume>:<fpage>476</fpage>-<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr10-0148607111416483">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cannell</surname><given-names>JJ</given-names></name>
<name><surname>Vieth</surname><given-names>R</given-names></name>
<name><surname>Umhau</surname><given-names>JC</given-names></name>
<etal/>
</person-group>. <article-title>Epidemic influenza and vitamin D</article-title>. <source>Epidemiol Infect</source>. <year>2006</year>;<volume>134</volume>:<fpage>1129</fpage>-<lpage>1140</lpage>.</citation>
</ref>
<ref id="bibr11-0148607111416483">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martineau</surname><given-names>AR</given-names></name>
<name><surname>Wilkinson</surname><given-names>RJ</given-names></name>
<name><surname>Wilkinson</surname><given-names>KA</given-names></name>
<etal/>
</person-group>. <article-title>A single dose of vitamin D enhances immunity to mycobacteria</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2007</year>;<volume>176</volume>:<fpage>208</fpage>-<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr12-0148607111416483">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Raman</surname><given-names>M</given-names></name>
<name><surname>Milestone</surname><given-names>AN</given-names></name>
<name><surname>Walters</surname><given-names>J</given-names></name>
<name><surname>Hart</surname><given-names>AL</given-names></name>
<name><surname>Ghosh</surname><given-names>S</given-names></name>
</person-group>. <article-title>Vitamin D and gastrointestinal diseases: inflammatory bowel disease and colorectal cancer</article-title>. <source>Ther Adv Gastroenterol</source>. <year>2011</year>;<volume>4</volume>:<fpage>49</fpage>-<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr13-0148607111416483">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhall</surname><given-names>AK</given-names></name>
<name><surname>Amento</surname><given-names>EP</given-names></name>
<name><surname>Thomas</surname><given-names>LC</given-names></name>
<name><surname>Holick</surname><given-names>MF</given-names></name>
<name><surname>Krane</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1983</year>;<volume>57</volume>:<fpage>1308</fpage>-<lpage>1310</lpage>.</citation>
</ref>
<ref id="bibr14-0148607111416483">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Provvedini</surname><given-names>DM</given-names></name>
<name><surname>Tsoukas</surname><given-names>CD</given-names></name>
<name><surname>Deftos</surname><given-names>LJ</given-names></name>
<name><surname>Manolagas</surname><given-names>SC</given-names></name>
</person-group>. <article-title>1,25-Dihydroxyvitamin D3 receptors in human leukocytes</article-title>. <source>Science</source>. <year>1983</year>;<volume>221</volume>:<fpage>1181</fpage>-<lpage>1183</lpage>.</citation>
</ref>
<ref id="bibr15-0148607111416483">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brennan</surname><given-names>A</given-names></name>
<name><surname>Katz</surname><given-names>DR</given-names></name>
<name><surname>Nunn</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Dendritic cells from human tissue express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol</article-title>. <source>Immunology</source>. <year>1987</year>;<volume>61</volume>:<fpage>457</fpage>-<lpage>461</lpage>.</citation>
</ref>
<ref id="bibr16-0148607111416483">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Veldman</surname><given-names>CM</given-names></name>
<name><surname>Cantorna</surname><given-names>MT</given-names></name>
<name><surname>DeLuca</surname><given-names>HF</given-names></name>
</person-group>. <article-title>Expression of 1,25-dihydroxyvitamin D3 receptor in the immune system</article-title>. <source>Arch Biochem Biophys</source>. <year>2000</year>;<volume>374</volume>:<fpage>334</fpage>-<lpage>338</lpage>.</citation>
</ref>
<ref id="bibr17-0148607111416483">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Avenell</surname><given-names>A</given-names></name>
<name><surname>Cook</surname><given-names>JA</given-names></name>
<name><surname>Maclennan</surname><given-names>GS</given-names></name>
<name><surname>Macpherson</surname><given-names>GC</given-names></name>
</person-group>. <article-title>Vitamin D supplementation to prevent infections: a sub-study of a randomised placebo-controlled trial in older people</article-title>. <source>Age Ageing</source>. <year>2007</year>;<volume>36</volume>:<fpage>574</fpage>-<lpage>577</lpage>.</citation>
</ref>
<ref id="bibr18-0148607111416483">
<label>18.</label>
<citation citation-type="book">
<collab>Institute of Medicine (IOM)</collab>. <source>Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>; <year>1997</year>.</citation>
</ref>
<ref id="bibr19-0148607111416483">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DeLuca</surname><given-names>H</given-names></name>
</person-group>. <article-title>Vitamin D and the parenteral nutrition patient</article-title>. <source>Gastroenterology</source>. <year>2009</year>; <volume>137</volume>: <fpage>S79</fpage>-<lpage>S91</lpage>.</citation>
</ref>
<ref id="bibr20-0148607111416483">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lappe</surname><given-names>JM</given-names></name>
<name><surname>Davies</surname><given-names>KM</given-names></name>
<name><surname>Travers-Gustafson</surname><given-names>D</given-names></name>
<name><surname>Heaney</surname><given-names>RP</given-names></name>
</person-group>. <article-title>Vitamin D status in a rural postmenopausal female population</article-title>. <source>J Am Coll Nutr</source>. <year>2006</year>;<volume>25</volume>:<fpage>395</fpage>-<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr21-0148607111416483">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Corey</surname><given-names>B</given-names></name>
<name><surname>Ackerman</surname><given-names>K</given-names></name>
<name><surname>Allen</surname><given-names>P</given-names></name>
<name><surname>Sceery</surname><given-names>N</given-names></name>
<name><surname>Rafoth</surname><given-names>C</given-names></name>
</person-group>. <article-title>Vitamin D status of New England home TPN patients: a snapshot of practice</article-title>. <source>Nutr Clin Pract</source>. <year>2009</year>; <volume>24</volume>: <fpage>110A</fpage>.</citation>
</ref>
<ref id="bibr22-0148607111416483">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thomson</surname><given-names>P</given-names></name>
<name><surname>Duerksen</surname><given-names>D</given-names></name>
</person-group>. <article-title>Vitamin D deficiency in patients receiving home parenteral nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2011</year>;<volume>35</volume>:<fpage>499</fpage>-<lpage>504</lpage>.</citation>
</ref>
<ref id="bibr23-0148607111416483">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Staun</surname><given-names>M</given-names></name>
<name><surname>Pironi</surname><given-names>L</given-names></name>
<name><surname>Bozzetti</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>ESPEN Guidelines on Parenteral Nutrition: home parenteral nutrition (HPN) in adult patients</article-title>. <source>Clin Nutr</source>. <year>2009</year>;<volume>28</volume>:<fpage>467</fpage>-<lpage>479</lpage>.</citation>
</ref>
<ref id="bibr24-0148607111416483">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wengler</surname><given-names>A</given-names></name>
<name><surname>Micklewright</surname><given-names>A</given-names></name>
<name><surname>Hebuterne</surname><given-names>X</given-names></name>
<etal/>
</person-group>. <article-title>Monitoring of patients on home parenteral nutrition (HPN) in Europe: a questionnaire based study on monitoring practice in 42 centers</article-title>. <source>Clin Nutr</source>. <year>2006</year>;<volume>25</volume>:<fpage>693</fpage>-<lpage>700</lpage>.</citation>
</ref>
<ref id="bibr25-0148607111416483">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gillanders</surname><given-names>L</given-names></name>
<name><surname>Angstmann</surname><given-names>K</given-names></name>
<name><surname>Ball</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>AuSPEN clinical practice guideline for home parenteral nutrition patients in Australia and New Zealand</article-title>. <source>Nutrition</source>. <year>2008</year>;<volume>24</volume>:<fpage>998</fpage>-<lpage>1012</lpage>.</citation>
</ref>
<ref id="bibr26-0148607111416483">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kovacevich</surname><given-names>DS</given-names></name>
<name><surname>Frederick</surname><given-names>A</given-names></name>
<name><surname>Kelly</surname><given-names>D</given-names></name>
<name><surname>Nishikawa</surname><given-names>R</given-names></name>
<name><surname>Young</surname><given-names>L</given-names></name>
</person-group>. <article-title>Standards for specialized nutrition support: home care patients</article-title>. <source>Nutr Clin Pract</source>. <year>2005</year>;<volume>20</volume>:<fpage>579</fpage>-<lpage>590</lpage>.</citation>
</ref>
<ref id="bibr27-0148607111416483">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siepler</surname><given-names>J</given-names></name>
</person-group>. <article-title>Principles and strategies for monitoring home parenteral nutrition</article-title>. <source>Nutr Clin Pract</source>. <year>2007</year>;<volume>22</volume>:<fpage>340</fpage>-<lpage>350</lpage>.</citation>
</ref>
<ref id="bibr28-0148607111416483">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Messing</surname><given-names>B</given-names></name>
<name><surname>Joly</surname><given-names>F</given-names></name>
</person-group>. <article-title>Guidelines for management of home parenteral support in adult chronic intestinal failure patients</article-title>. <source>Gastroenterology</source>. <year>2006</year>; <volume>130</volume>: <fpage>S43</fpage>-<lpage>S51</lpage>.</citation>
</ref>
<ref id="bibr29-0148607111416483">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boullata</surname><given-names>J</given-names></name>
<name><surname>Compher</surname><given-names>C</given-names></name>
<name><surname>Schiavone</surname><given-names>P</given-names></name>
<name><surname>Stoner</surname><given-names>H</given-names></name>
<name><surname>Hoff</surname><given-names>K</given-names></name>
<name><surname>Kinosian</surname><given-names>B</given-names></name>
</person-group>. <article-title>Oral vitamin D repletion in patients with parenteral nutrition-dependent intestinal failure</article-title>. <source>Nutr Clin Pract</source>. <year>2009</year>; <volume>24</volume>: <fpage>138</fpage>.</citation>
</ref>
<ref id="bibr30-0148607111416483">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vieth</surname><given-names>R</given-names></name>
</person-group>. <article-title>Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety</article-title>. <source>Am J Clin Nutr</source>. <year>1999</year>;<volume>69</volume>:<fpage>842</fpage>-<lpage>856</lpage>.</citation>
</ref>
<ref id="bibr31-0148607111416483">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Raman</surname><given-names>M</given-names></name>
<name><surname>Aghdassi</surname><given-names>E</given-names></name>
<name><surname>Baun</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Metabolic bone disease in patients receiving home parenteral nutrition: a Canadian study and review</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2006</year>;<volume>30</volume>:<fpage>492</fpage>-<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr32-0148607111416483">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Higgins</surname><given-names>D</given-names></name>
<name><surname>Wischmeyer</surname><given-names>P</given-names></name>
<name><surname>Queensland</surname><given-names>K</given-names></name>
<name><surname>Sillau</surname><given-names>S</given-names></name>
<name><surname>Sufit</surname><given-names>A</given-names></name>
<name><surname>Heyland</surname><given-names>D</given-names></name>
</person-group>. <article-title>Relationship of vitamin D deficiency to clinical outcomes in critically ill patients</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2011</year>; <volume>35</volume>: <fpage>S31</fpage>.</citation>
</ref>
<ref id="bibr33-0148607111416483">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>P</given-names></name>
<name><surname>Eisman</surname><given-names>JA</given-names></name>
<name><surname>Center</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Vitamin D deficiency in critically ill patients</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>18</issue>):<fpage>1912</fpage>-<lpage>1914</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>